Cargando…

A fatal case of daclizumab-induced liver failure in a patient with MS

Detalles Bibliográficos
Autores principales:	Stettner, Mark, Gross, Catharina C., Mausberg, Anne K., Pul, Refik, Junker, Andreas, Baba, Hideo A., Schulte-Mecklenbeck, Andreas, Wiendl, Heinz, Kleinschnitz, Christoph, Meuth, Sven G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2019
Materias:	Clinical/Scientific Notes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369971/ https://www.ncbi.nlm.nih.gov/pubmed/30800722 http://dx.doi.org/10.1212/NXI.0000000000000539

Ejemplares similares

Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy in MS
por: Scheibe, Franziska, et al.
Publicado: (2018)

Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells
por: Ruck, Tobias, et al.
Publicado: (2018)

Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Increased Intrathecal B and Plasma Cells in Patients With Anti-IgLON5 Disease: A Case Series
por: Strippel, Christine, et al.
Publicado: (2022)

Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort study
por: Ruck, Tobias, et al.
Publicado: (2019)

Severe and long-lasting alteration of albumin redox state by plasmapheresis
por: Boss, Kristina, et al.
Publicado: (2022)

Fulminant MS Reactivation Following Combined Fingolimod Cessation and Yellow Fever Vaccination
por: Rolfes, Leoni, et al.
Publicado: (2019)

A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS
por: Rolfes, Leoni, et al.
Publicado: (2019)

Generation of a Model to Predict Differentiation and Migration of Lymphocyte Subsets under Homeostatic and CNS Autoinflammatory Conditions
por: Gross, Catharina C., et al.
Publicado: (2020)

Onconeural antigen spreading in paraneoplastic neurological disease due to small cell lung cancer
por: Dik, Andre, et al.
Publicado: (2018)

Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

The Innate Immune Response Characterizes Posterior Reversible Encephalopathy Syndrome
por: Nelke, Christopher, et al.
Publicado: (2021)

Autoimmunity complicating SARS-CoV-2 infection in selective IgA-deficiency
por: Pfeuffer, Steffen, et al.
Publicado: (2020)

Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment
por: Rolfes, Leoni, et al.
Publicado: (2021)

Immune Cell Profiling of the Cerebrospinal Fluid Provides Pathogenetic Insights Into Inflammatory Neuropathies
por: Heming, Michael, et al.
Publicado: (2019)

Treating refractory post-herpetic anti-N-methyl-d-aspartate receptor encephalitis with rituximab
por: Strippel, Christine, et al.
Publicado: (2017)

Ineffective treatment of PML with pembrolizumab: Exhausted memory T-cell subsets as a clue?
por: Pawlitzki, Marc, et al.
Publicado: (2019)

Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis
por: Gross, Catharina C., et al.
Publicado: (2015)

Neurocognitive decline in HIV patients is associated with ongoing T-cell activation in the cerebrospinal fluid
por: Grauer, Oliver M, et al.
Publicado: (2015)

Cerebrospinal Fluid Concentrations of Neuronal Proteins Are Reduced in Primary Angiitis of the Central Nervous System
por: Ruland, Tillmann, et al.
Publicado: (2018)

Signatures of immune reprogramming in anti-CD52 therapy of MS: markers for risk stratification and treatment response
por: Bierhansl, Laura, et al.
Publicado: (2019)

Impact of disease‐modifying therapies on humoral and cellular immune‐responses following SARS‐CoV‐2 vaccination in MS patients
por: Trümpelmann, Susan, et al.
Publicado: (2022)

Comparing Plasma Exchange to Escalated Methyl Prednisolone in Refractory Multiple Sclerosis Relapses
por: Pfeuffer, Steffen, et al.
Publicado: (2019)

High anti-JCPyV serum titers coincide with high CSF cell counts in RRMS patients
por: Schneider-Hohendorf, Tilman, et al.
Publicado: (2020)

Amyotrophic lateral sclerosis patients show increased peripheral and intrathecal T-cell activation
por: Rolfes, Leoni, et al.
Publicado: (2021)

Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses
por: Pfeuffer, Steffen, et al.
Publicado: (2022)

Regulatory Functions of Natural Killer Cells in Multiple Sclerosis
por: Gross, Catharina C., et al.
Publicado: (2016)

MOG antibody–associated encephalomyelitis mimicking bacterial meningomyelitis following ChAdOx1 nCoV-19 vaccination: a case report
por: Escolà, Jordi Kühne, et al.
Publicado: (2022)

Immune Cell Profiling During Switching from Natalizumab to Fingolimod Reveals Differential Effects on Systemic Immune-Regulatory Networks and on Trafficking of Non-T Cell Populations into the Cerebrospinal Fluid—Results from the ToFingo Successor Study
por: Lohmann, Lisa, et al.
Publicado: (2018)

Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis
por: Gross, Catharina C., et al.
Publicado: (2016)

GFAPα IgG-associated encephalitis upon daclizumab treatment of MS
por: Luessi, Felix, et al.
Publicado: (2018)

Management of MS Patients Treated With Daclizumab – a Case Series of 267 Patients
por: Rommer, Paulus S., et al.
Publicado: (2020)

Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis
por: Schafflick, David, et al.
Publicado: (2020)

Evaluation of Age-Dependent Immune Signatures in Patients With Multiple Sclerosis
por: Eschborn, Melanie, et al.
Publicado: (2021)

Cerebrospinal fluid flow cytometry distinguishes psychosis spectrum disorders from differential diagnoses
por: Räuber, Saskia, et al.
Publicado: (2021)

Cytotoxic CD8(+) T cells and CD138(+) plasma cells prevail in cerebrospinal fluid in non-paraneoplastic cerebellar ataxia with contactin-associated protein-2 antibodies
por: Melzer, Nico, et al.
Publicado: (2012)

Patients with MS under daclizumab therapy mount normal immune responses to influenza vaccination
por: Lin, Yen Chih, et al.
Publicado: (2016)

Enhanced pathogenicity of Th17 cells due to natalizumab treatment: Implications for MS disease rebound
por: Janoschka, Claudia, et al.
Publicado: (2022)

Contactin-associated protein 2 autoantibodies can be associated with multifocal motor-like neuropathy: a case report
por: Müller-Miny, Louisa, et al.
Publicado: (2023)

Endocarditis following ocrelizumab in relapsing-remitting MS
por: Faissner, Simon, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qajni46f256vqe8g8th5tns3e5